LY 3202626

Drug Profile

LY 3202626

Alternative Names: LY3202626

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antidementias
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Singapore (PO) (NCT03023826)
  • 01 Jun 2016 Phase-II clinical trials in Alzheimer's disease (In the elderly) in USA (PO) (NCT02791191)
  • 01 Jun 2016 Eli Lilly plans a phase II trial in Alzheimer's disease dementia in USA, Australia, Canada and Japan (NCT02791191)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top